Vis børsmeldingen
Oslo, September 21 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical
stage leader in immune stimulatory vaccines for cancer, announced today that
further data from its clinical study on the combination of its universal cancer
vaccine, UV1, and the PD-1 checkpoint inhibitor, pembrolizumab, will be
disclosed in an oral presentation at the 19(th) International Congress of the
Society for Melanoma Research (SMR) on 18 October 2022.
The presenter will be Dr. Yousef Zakharia, Investigator for the UV1-103 clinical
trial. Dr. Zakharia is a Medical Oncologist, Clinical Associate Professor and
Director Phase I Program at University of Iowa Hospital and Clinics.
“I am pleased to present the results from the UV1-103 trial to international
peers in melanoma research”, said Dr. Yousef Zakharia. Carlos de Sousa, CEO of
Ultimovacs added: “As Ultimovacs’ five randomized phase II trials of UV1
continue to mature, there is growing interest in the ability of the vaccine to
induce long-lasting, survival-associated immune responses. We are honored to be
able to present further data on the clinical activity of UV1.”
Ultimovacs’ presentation is entitled ‘Clinical Activity of Combined Telomerase
Vaccination and Pembrolizumab in Unresectable Melanoma’ and will be given as an
oral presentation at the International Congress of the Society for Melanoma
Research. Society for Melanoma Research will be online and in-person in
Edinburgh, UK, October 17 - 20, 2022. The congress brings together the leaders
in the field of basic and translational melanoma research and melanoma clinical
trial physicians from around the world.
The presentation will be made available at the Company website on October
18, 2022.
About the UV1-103 phase I trial in Malignant Melanoma
This US-based Phase I clinical trial is evaluating the Company’s lead candidate,
UV1, in combination with PD-1 checkpoint inhibitor, pembrolizumab, as a first-
line treatment in patients with metastatic malignant melanoma. The clinical
results for the 30 patients enrolled are:
- Objective response rate (ORR): 57%, complete response rate (CR): 33%
- Median Progression Free Survival (mPFS): 18.9 months (as measured by
iRECIST)
- Overall survival after 12 months: 87%, overall survival after 24 months: 73%
Patients will continue to be followed for long-term survival. UV1 has
demonstrated a good safety profile, and no unexpected safety issues related to
UV1 have been observed in this trial.
The U.S. Food and Drug Administration (FDA) granted a dual Fast Track
designation for UV1 in combination with checkpoint inhibitors in the treatment
of unresectable or metastatic melanoma - either as add-on therapy to
pembrolizumab or as add-on therapy to ipilimumab. Ultimovacs is currently
evaluating UV1 as add-on therapy to ipilimumab and nivolumab as first-line
treatment for unresectable or metastatic melanoma in a Phase II study named
INITIUM.
About Ultimovacs
Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to
treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine
candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in
all stages of tumor growth. By directing?the immune system to hTERT antigens,
UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade
and increase anti-tumor responses. With a broad Phase II program in five cancer
indications enrolling more than 650 patients, Ultimovacs aims to clinically
demonstrate UV1’s impact in multiple cancer types, in combination with other
immunotherapies, for patients with unmet needs. Ultimovacs’ second technology
approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform,
combines tumor-specific peptides and adjuvant in the same molecule and entered
Phase I studies in 2021.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Anne Worsøe, Head of Investor Relations
Email: ir@ultimovacs.com
Phone: +47 906 86 815
Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com
Phone: +44 7483 284?853
Kilde